Perspective Therapeutics, Inc. (CATX) stock
CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.75−0.03 (-3.85%)
Close on Nov 20, 2026Market cap $86.05MP/E –Yield –
Perspective Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Perspective Therapeutics's revenue for the twelve months ending Jun 30, 2022 was $10.80M, up 7.4% year over year. For fiscal 2022 it was $10.80M, up 7.4% from the year before. Over ten years it grew 7.8% a year on average. The highest annual figure on record is $10.80M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Jun 30, 2022 | $10.80M | +7.4% |
| FY2021 | Jun 30, 2021 | $10.05M | +3.9% |
| FY2020 | Jun 30, 2020 | $9.68M | +32.3% |
| FY2019 | Jun 30, 2019 | $7.31M | +23.5% |
| FY2018 | Jun 30, 2018 | $5.92M | +24.4% |
| FY2017 | Jun 30, 2017 | $4.76M | -0.2% |
| FY2016 | Jun 30, 2016 | $4.77M | +3.5% |
| FY2015 | Jun 30, 2015 | $4.61M | +9.2% |
| FY2014 | Jun 30, 2014 | $4.22M | -6.8% |
| FY2013 | Jun 30, 2013 | $4.53M | -10.8% |
| FY2012 | Jun 30, 2012 | $5.07M | -3.2% |
| FY2011 | Jun 30, 2011 | $5.24M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $2.51M | -7.6% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $2.91M | +11.9% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $2.82M | +19.4% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $2.56M | +7.6% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $2.71M | +18.9% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $2.60M | -9.7% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $2.36M | +6.9% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $2.38M | +3.0% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $2.28M | +18.5% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $2.88M | +49.7% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $2.21M | +15.9% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $2.32M | +48.2% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $1.92M | +20.0% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $1.92M | +22.3% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $1.90M | +24.0% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $1.56M | +29.0% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $1.60M | +17.0% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $1.57M | +22.7% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $1.54M | +49.4% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $1.21M | +12.0% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $1.37M | +22.3% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $1.28M | +7.0% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $1.03M | -13.5% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $1.08M | -14.3% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $1.12M | -16.5% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $1.20M | +3.4% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $1.19M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $1.26M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $1.34M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $1.16M | – |
See a number that looks wrong?